Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit
Morphic Therapeutic (NASDAQ: MORF) announced participation in the Jefferies Next Generation IBD Therapeutics Virtual Summit on September 23, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Morphic Therapeutic (NASDAQ: MORF) announced participation in the Jefferies Next Generation IBD Therapeutics Virtual Summit on September 23, 2020. The management team will engage in a panel discussion at 8:45 a.m. ET and present a company overview at 1:00 p.m. ET. A live webcast will be accessible via the Investor section of Morphic's website, with an archived replay available post-conference. Morphic specializes in developing oral therapies targeting integrins to treat serious chronic diseases, using its proprietary MInT technology platform in collaborations with major pharmaceutical firms.
Details
News Market Reaction – MORF
The recorded move for MORF in the trading session of this news was -1.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD Therapeutics Virtual Summit. Members of the Morphic management team are scheduled to participate in a panel discussion at 8:45 a.m. ET on Wednesday, September 23, 2020, as well as present a company overview at 1:00 p.m. ET on the same day.
A live webcast of the company presentation will be available on the Investor section of Morphic’s website at https://www.morphictx.com. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
Media Contact
Tom Donovan, Ten Bridge Communications
tom@tenbridgecommunications.com
857.559.3397
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.